Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Cerebrolysin (CERE) is a research peptide, at the approved (europe, asia) stage in the published literature. Complex mixture of neuropeptides derived from pig brain. Used in Europe and Asia for stroke and cognitive disorders.
Complex mixture of neuropeptides derived from pig brain. Used in Europe and Asia for stroke and cognitive disorders.
| Research Status | Approved (Europe, Asia) |
|---|---|
| Half-Life | Variable (mixture) |
| Administration | IV or IM injection |
| Doses Reported in Published Studies | 5-30 mL IV |
Multiple neurotrophic factors that promote neuroplasticity, neuroprotection, and neurogenesis.
Complex mixture of neuropeptides derived from pig brain. Used in Europe and Asia for stroke and cognitive disorders.
Multiple neurotrophic factors that promote neuroplasticity, neuroprotection, and neurogenesis.
Cerebrolysin is at the following stage in the published literature: Approved (Europe, Asia). All information is for research and educational purposes only.
Reported half-life: Variable (mixture).
Reported administration route in the literature: IV or IM injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.